stockrowNovo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) Revenue
Novo Nordisk A/S's revenue for fiscal 2025 was $46.8B, up 11.1% from $42.1B in fiscal 2024. Over the twelve months to 30 June 2026 it was $51.5B. Over the past ten years it has ranged from $16.1B (fiscal 2015) to $46.8B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 10 consecutive fiscal years. Novo Nordisk A/S ranks 9th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $46.8B | 11.12% |
| FY2024 | $42.1B | 24.86% |
| FY2023 | $33.7B | 34.59% |
| FY2022 | $25.1B | 11.85% |
| FY2021 | $22.4B | 15.18% |
| FY2020 | $19.4B | 6.33% |
| FY2019 | $18.3B | 6.97% |
| FY2018 | $17.1B | 0.78% |
| FY2017 | $17.0B | 2.14% |
| FY2016 | $16.6B | 3.43% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $12.2B | (19.45%) |
| Mar 2026 | $15.2B | 22.84% |
| Dec 2025 | $12.3B | 5.13% |
| Sep 2025 | $11.7B | 0.44% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| PFE Pfizer Inc. compare | $63.6B |
| AZN AstraZeneca PLC compare | $62.4B |
| SNY Sanofi compare | $59.1B |
| NVS Novartis AG compare | $57.4B |
| NVO Novo Nordisk A/S | $51.5B |
| BMY Bristol Myers Squibb Company compare | $50.0B |
| GSK GSK PLC Sponsored ADR compare | $44.9B |
| AMGN Amgen Inc. compare | $38.9B |
| GILD Gilead Sciences, Inc. compare | $31.0B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on NVO
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement